Targeted agents in cancer therapy

Medicine

Volumn 36, Issue 1, 2008, Pages 33-37

  Arkenau, Hendrik Tobias ^a,b,c   Carden, Craig P ^a,b,c   de Bono, Johann S ^a,b,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Department of Histopathology   (Australia)

Author keywords

biological agents; cancer therapy; monoclonal antibody; tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; DASATINIB; ERLOTINIB; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEFITINIB; GEMCITABINE; IMATINIB; INTERLEUKIN 2; IRINOTECAN; LAPATINIB; LETROZOLE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SKIN DISCOLORATION; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

EID: 37749021122     PISSN: 13573039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpmed.2007.10.007     Document Type: Review

References (30)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. GLOBOCAN database. Cancer incidence, mortality and prevalence worldwide (2002 estimates). Available at: www-dep.iarc.fr/globocan/database (accessed 11 October 2007).
3. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
4. Shepherd F.A., Pereira J., Ciuleanu T.E., et al. Erlotinib in previously tested non-small cell lung cancer. N Engl J Med 353 (2005) 123-132
5. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
6. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE. A Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
7. Riely G.J., Pao W., Pham D., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12 (2006) 839-844
8. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 542-550
9. McPherson K., Steel C.M., and Dixon J.M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. Br Med J 321 (2000) 624-628
10. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Eng J Med 344 (2001) 783-792
11. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
12. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
13. Zon R, Miller K, Wang M, et al. A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern Cooperative Oncology Group trial E2100. Presented at 5th European Breast Cancer Conference (EBCC-5) 2006; abstract No 7.
14. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus Capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
15. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
16. van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO 2007, abstract 4000.
17. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350 (2004) 2335-2342
18. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23 (2005) 2
19. Cassidy J, Clarke S, Diaz Rubio E, et al. XELOX vs FOLFOX4: efficacy result from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). Presented at the Gastrointestinal Cancer Symposium, ASCO 2007, abstract 270.
20. Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Presented at the Gastrointestinal Cancer Symposium, ASCO 2006, abstract 237.
21. De Mulder P.H.M., Van Herpen C.M.L., and Mulders P.A.F. Current treatment of renal cell carcinoma. Ann Oncol 15 suppl 4 (2004) 319-328
22. Hainsworth J.D., Sosman J.A., Spigel D.R., et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 31 (2005) 7889-7896
23. Escoudier B., Szczylik C., Eisen T., et al. Randomized phase-III trial of the Raf kinase VEGFR inhibitor sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23 (2005) 4510
24. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
25. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
26. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 23 16S (2005) 1
27. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Presented at the Gastrointestinal Cancer Symposium, ASCO 2007, abstract 108.
28. Posner M.R., and Wirth L.J. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med 354 (2006) 634-636
29. Van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
30. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 368 (2006) 1303-1304